Mammary Cell News 8.43 November 3, 2016 | |
| |
TOP STORYThe identities of stem/progenitor cell populations, as well as tumor-initiating cells that give rise to breast cancer are incompletely understood. The authors showed that Lgr6 marks rare populations of cells in both basal and luminal mammary gland compartments in mice. [Nat Cell Biol] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHProdigiosin Inhibits Wnt/β-Catenin Signaling and Exerts Anticancer Activity in Breast Cancer Cells In breast cancer cells, pharmacologic inhibitors of GSK3β have been reported to prevent prodigiosin toxicity. Inhibitors of GSK3β promote β-catenin–dependent Wnt pathway activation. These results prompted the authors to assess the effects of prodigiosin on Wnt/β-catenin signaling. [Proc Natl Acad Sci USA] Full Article Stromal PTEN Inhibits the Expansion of Mammary Epithelial Stem Cells through Jagged-1 Scientists evaluated both phenotypic and genetic changes within the pre-neoplastic mammary epithelium of mice with and without stromal phosphatase and tensin homolog (PTEN) expression. [Oncogene] Abstract The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-Like Breast Cancer Investigators report that Slug undergoes acetylation-dependent protein degradation and identify the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilizes Slug, whereas SIRT2 overexpression extends Slug stability. [Cell Rep] Abstract | Press Release | Graphical Abstract 3D Bioprinting a Cell-Laden Bone Matrix for Breast Cancer Metastasis Study Scientists developed a biomimetic bone matrix using 3D bioprinting technology and investigated the interaction between breast cancer cells and bone stromal cells. [ACS Appl Mater Interfaces] Abstract | Graphical Abstract Investigators recorded fluorescence images of allophycocyanin-epithelial cell adhesion molecule (EpCAM) in cancer cell lines using a plasmonic chip and the distribution of EpCAM within the cell on the chip was determined. [ACS Appl Mater Interfaces] Abstract | Graphical Abstract Cisplatin is an effective breast cancer drug but resistance often develops over prolonged chemotherapy. Scientists performed a candidate approach RNAi screen in combination with cisplatin treatment to identify molecular pathways conferring survival advantages. [Oncotarget] Full Article TIGAR Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer Researchers determined the effects of TP53 Inducible Glycolysis and Apoptosis Regulator (TIGAR) expression on breast carcinoma and fibroblast glycolytic phenotype and tumor growth. [J Biol Chem] Full Article CLINICAL RESEARCHCaspase-3 and Caspase-8 Expression in Breast Cancer: Caspase-3 Is Associated with Survival Scientists investigated the prognostic potential of caspase-3 and -8 in breast cancer, as well as the prognostic value of combinatorial caspase and calpain expression. [Apoptosis] Full Article GLUL Promotes Cell Proliferation in Breast Cancer The authors found that higher expression of glutamate-ammonia ligase (GLUL) in breast cancer patients was associated with larger tumor size and higher level of HER2 expression. [J Cell Biochem] Abstract | |
| |
REVIEWSThis review outlines multiple functions of USP18 in the regulation of various immunological processes, including pathogen control, cancer development, and autoimmune diseases. [Cell Death Dis] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSNovartis announced that the US Food and Drug Administration (FDA) accepted the company’s New Drug Application for filing and granted Priority Review for LEE011 as first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2–) advanced or metastatic breast cancer in combination with letrozole. [Novartis] Press Release Exploring Pathway Messaging in the Development of Triple-Negative Breast Cancer Rutgers Cancer Institute of New Jersey researcher Michael L. Gatza, PhD, has received a $200,000 V Scholar Grant from The V Foundation for Cancer Research to explore a cell pathway in triple-negative breast cancer. [Rutgers Cancer Institute of New Jersey] Press Release Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced that they have established a new drug discovery company called Bridge Medicines. [Memorial Sloan Kettering Cancer Center] Press Release | |
| |
POLICY NEWSTracker Flags Up Failures to Report Clinical Trials An automated tool has trawled through thousands of records on the world’s leading clinical-trials database to reveal which drug firms and academic institutions are failing to publish the results of their trials. The US Department of Health and Human Services announced tougher rules to push the researchers that it funds to publish clinical-trial designs and results. [Nature News] Editorial Publisher Pulls 58 Articles by Iranian Scientists over Authorship Manipulation A tranche of 58 articles authored by 282 Iran-based researchers were retracted by a leading scientific publisher, which said it had found signs that the peer review and publication processes had been compromised. [Nature News] Editorial Young Scientists Ditch Postdocs for Biotech Start-Ups There is a vanguard of young biomedical scientists who have started companies instead of taking the conventional academic path and pursuing postdoctoral studies after their PhDs. Among the factors driving this change are an infusion of money into early-stage biotech investing, the emergence of biotech incubators and the scarcity of academic jobs in science. [Nature News] Editorial Beyond Trump vs Clinton: A Scientist’s Guide to the US Election Choices that voters make will influence other levels of government — and some of these decisions will steer the course of science and science policy. [Nature News] Editorial
| |
EVENTSNEW 2017 European Cancer Congress Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Breast Cancer Epidemiology (Karolinska Institutet) NEW Postdoctoral Research Associate – Breast Cancer Bone Metastasis (University of Sheffield) Postdoctoral Position – Immunology (Inserm) Postdoctoral Training Fellow (Institute of Cancer Research) Research Associate – Patient-Derived Organoid Models of Breast Cancer (King’s College London) Postdoctoral Fellow – BioMarker Research Cancer (Houston Methodist Research Institute) Postdoctoral Associate – Mammary Stem Cell and Cancer Biology (University of Miami) Postdoctoral Position – Neovascularization and Cancer Biology (The Ohio State University) Postdoctoral Associate – Functional Genomics and Cancer (The Jackson Laboratory) Assistant Professor – Physiology and Biophysics (University of Illinois at Chicago) Postdoctoral Researcher – Breast Cancer (Purdue University) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.43 | Nov 3 2016